[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR115384A1 - Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer - Google Patents

Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer

Info

Publication number
AR115384A1
AR115384A1 ARP190101254A ARP190101254A AR115384A1 AR 115384 A1 AR115384 A1 AR 115384A1 AR P190101254 A ARP190101254 A AR P190101254A AR P190101254 A ARP190101254 A AR P190101254A AR 115384 A1 AR115384 A1 AR 115384A1
Authority
AR
Argentina
Prior art keywords
ring
alkyl
treatment
formula
optionally
Prior art date
Application number
ARP190101254A
Other languages
English (en)
Inventor
Jason Grant Kettle
David Buttar
Gillian Mgregor Lamont
Frederick Woolf Goldberg
Attilla Kuan Tsuei Ting
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AR115384A1 publication Critical patent/AR115384A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a compuestos de fórmula (1), o sales farmacéuticas aceptables de los mismos, en donde R¹, R², X, el anillo A, el anillo B y el anillo C tienen cualquiera de los significados definidos anteriormente en el presente documento en la descripción; a procesos para su preparación; a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de enfermedades mediadas por MCT4. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéutica aceptable del mismo, en donde: R¹ y R² representan cada uno independientemente hidrógeno o metilo; X representa CH₂ u O; el anillo A y el anillo B representan cada uno independientemente un anillo seleccionado entre fenilo, piridinilo, pirazinilo, pirimidinilo y piridazinilo, en donde cada uno del anillo A y el anillo B están opcionalmente sustituidos de manera independiente con uno o más sustituyentes seleccionados entre alquilo C₁₋₃ y alcoxi C₁₋₃; el anillo C representa un heterocicloalquilo saturado monocíclico o bicíclico de 5 a 9 miembros que contiene opcionalmente uno o más heteroátomos adicionales seleccionados independientemente entre O, N y S, en donde el anillo C está opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C₁₋₃, opcionalmente sustituido con metoxi o hidroxilo; dioxo, alquil C₀₋₂-C(O)N(Me)₂, C(O)alquilo C₁₋₂ y S(O)₂alquilo C₁₋₂.
ARP190101254A 2018-05-11 2019-05-10 Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer AR115384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11

Publications (1)

Publication Number Publication Date
AR115384A1 true AR115384A1 (es) 2021-01-13

Family

ID=66484070

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101254A AR115384A1 (es) 2018-05-11 2019-05-10 Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer

Country Status (16)

Country Link
US (3) US11084827B2 (es)
EP (2) EP4134368A1 (es)
JP (1) JP7418353B2 (es)
KR (1) KR20210013078A (es)
CN (3) CN112469721B (es)
AR (1) AR115384A1 (es)
AU (1) AU2019264826B2 (es)
BR (1) BR112020023068A2 (es)
CA (1) CA3099579A1 (es)
DK (1) DK3790879T3 (es)
ES (1) ES2927244T3 (es)
MX (1) MX2020012058A (es)
PT (1) PT3790879T (es)
TW (1) TWI823932B (es)
UY (1) UY38228A (es)
WO (1) WO2019215316A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
US20230192704A1 (en) * 2020-05-21 2023-06-22 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
CN116801906A (zh) 2020-11-02 2023-09-22 阿雷斯贸易股份有限公司 癌症的联合治疗
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
EP4340843A1 (en) 2021-05-21 2024-03-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
WO2016118823A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
BR112017026535B1 (pt) * 2015-06-12 2023-12-19 Vettore, LLC Composto e composição farmacêutica
US20190135747A1 (en) * 2016-05-12 2019-05-09 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
CN112469721A (zh) 2021-03-09
US11851432B2 (en) 2023-12-26
ES2927244T3 (es) 2022-11-03
TWI823932B (zh) 2023-12-01
BR112020023068A2 (pt) 2021-02-09
UY38228A (es) 2019-10-31
CN115028637A (zh) 2022-09-09
JP2021523177A (ja) 2021-09-02
AU2019264826A1 (en) 2020-11-26
US20210340150A1 (en) 2021-11-04
WO2019215316A1 (en) 2019-11-14
CN115028637B (zh) 2024-03-22
CA3099579A1 (en) 2019-11-14
US11084827B2 (en) 2021-08-10
US20210087196A1 (en) 2021-03-25
EP4134368A1 (en) 2023-02-15
JP7418353B2 (ja) 2024-01-19
CN112469721B (zh) 2022-06-07
KR20210013078A (ko) 2021-02-03
DK3790879T3 (da) 2022-08-29
TW202015674A (zh) 2020-05-01
MX2020012058A (es) 2021-02-26
AU2019264826B2 (en) 2024-05-23
US20240217980A1 (en) 2024-07-04
EP3790879A1 (en) 2021-03-17
PT3790879T (pt) 2022-08-26
EP3790879B1 (en) 2022-06-29
CN115028636A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
AR115384A1 (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR116604A1 (es) Inhibidores de kras g12c
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
MX2019000123A (es) Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores.
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
AR103252A1 (es) Compuestos de quinazolina
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
AR108011A1 (es) Moduladores receptores de estrógenos
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
RU2020110780A (ru) Ингибитор fgfr и его медицинское применение
AR101177A1 (es) Inhibidores de la syk
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
ECSP15042779A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
AR094553A1 (es) Formas de oxadiazolpirazina
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR100694A1 (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer
AR109706A1 (es) INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g
AR086803A1 (es) Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras